New award for acetazolamide tablets with avkare. Ordering period is july 31, 2022 to july 30, 2023 with four one-year options

Active Indefinite Delivery Contract Awarded Last action

Contract number
36E79722D0025
Awardee
Awarding agency
Task orders
0

Award facts

Opportunity
Last date to order 85% complete
IDV ceiling
$2,075,624.60
Award type
Single award
Contracting staff
Set-aside
No set-aside
Competition
Full and Open Competition · 7 offers Negotiated Proposal / Quote
Pricing
Firm Fixed Price

Award details come from SAM.gov/FPDS.

About this IDV

The National Acquisition Center awarded a single-award indefinite delivery contract to Avkare LLC on July 31, 2022, for acetazolamide tablets with a ceiling value of $2,075,624.60. The contract carries no set-aside. The ordering period runs from July 31, 2022, through July 30, 2023, with four one-year options extending the ultimate completion date to July 30, 2027. Place of performance is Pulaski, Tennessee. The contract implements Executive Order 14398 on diversity, equity, and inclusion in federal procurement. The originating solicitation, posted March 2, 2022, with responses due March 24, 2022, sought acetazolamide tablets as a pharmaceutical supply item for federal healthcare beneficiaries. The contract is structured as a firm fixed-price commercial procurement under FAR Part 12 with no subcontract requirements noted in the award documentation.

Transactions

Action Obligated Date
Supplemental Agreement for work within scope P00011 · Implementing EO 14398 DEI discrimination $0
Exercise an Option P00010 · Exercise the fourth option year for acetazolamide tablets, contract 36E79722D0025, with avkare, LLC with no price changes. $0
Add Subcontract Plan P00009 · Incorporate avkare's 2026 subk plan into contract. Plan effective 1/1/2026 - 12/31/2026. $0
Exercise an Option P00008 · Exercise the third option year for acetazolamide tablets contract 36E79722D0025 with avkare, LLC with no price changes. $0
Add Subcontract Plan P00007 · Incorporate avkare's 2025 subk plan into contract. Plan effective 1/3/2025 - 12/31/2025. $0
Exercise an Option P00006 · Exercise the second option year for acetazolamide tablets contract 36E79722D0025 with avkare, LLC with no price changes. $0
Supplemental Agreement for work within scope P00005 · Update to cost recovery fee (CRF) and submission of quarterly sales reports 36E79722D0025, avkare, LLC for acetazolamide tablets. $0
Add Subcontract Plan P00004 · Implement avkare, LLC 2024 subk plan. $0
Exercise an Option P00003 · Exercise the first option year for acetazolamide tablets contract 36E79722D0025 with avkare, LLC with no price changes. $0
Other Administrative Action P00002 · Incorporate updated dscsa language and requirements into VA national contract 36E79722D0025. $0
Add Subcontract Plan P00001 · Far 52.219-9 small business subcontracting plan. Implement avkare, LLC 2023 subk plan. $0
Original award $0
Show all 12

Quick answers

Who was awarded contract 36E79722D0025?

36E79722D0025 was awarded to Avkare LLC by National Acquisition Center (Headquarters) on July 31, 2022.

How much is contract 36E79722D0025 worth?

36E79722D0025's own ceiling is $2,075,625.

Who can order from contract 36E79722D0025?

36E79722D0025 is a single award indefinite delivery contract.

Was contract 36E79722D0025 competed?

The extent of competition for 36E79722D0025 was full and open competition. The government received 7 offers.

On GovTribe

See this IDV's full record

  • Every order and transaction
  • The awardee's other awards and teaming partners
  • Similar IDVs and recompete opportunities
  • Ask GovTribe AI about this IDV